| Literature DB >> 29035735 |
Aditya Verma1, Vasundhra Bhandari2, Deepak Kumar Deep2, Shyam Sundar3, Jean Claude Dujardin4, Ruchi Singh2, Poonam Salotra5.
Abstract
Widespread resistance towards antimony and reports of relapses following miltefosine treatment has severely affected the management of visceral leishmaniasis (VL) in the Indian subcontinent. Paromomycin (PMM), an aminoglycoside antibiotic, has been licensed for VL treatment in India in 2007. Although its use is still restricted in the field, unraveling the molecular mechanism of resistance towards PMM is the key to preserve the drug. In this study, PMM resistant lines were selected up to 100 μM of PMM in three distinct field isolates of Leishmania donovani at promastigote stage. The resistance induced at promastigote level was also evident in amastigotes which showed 6 fold decreases in PMM susceptibility. Comparative transcriptome profiling of PMM resistant (PMM-R) and the corresponding PMM sensitive (PMM-S) parasites revealed modulated expression of 500 genes (1.5 fold cut off) in PMM-R parasites. Selected genes were validated for their modulated expression by quantitative real-time PCR. Functional classification and pathway analysis of modulated genes indicated probable adaptations in drug resistant lines which included a) reduced oxidative phosphorylation; b) increased glycosomal succinate fermentation and substrate level phosphorylation; c) dependency on lipids and amino acids for energy generation; d) reduced DNA synthesis and increased DNA damage repair and e) decreased protein synthesis and degradation. Interestingly, PMM-R parasites showed a marked increase in PMM susceptibility in presence of verapamil and amlodipine, antagonists of Ca2+ channel that are also modulators of ABC transporters. Moreover, infection of macrophages by PMM-R parasites led to modulated nitric oxide (NO) levels while reactive oxygen species (ROS) level remained unaltered. The present study highlights the putative mechanisms of PMM resistance in Leishmania.Entities:
Keywords: ABC transporters; Drug resistance; Leishmania donovani; Nitric oxide; Paromomycin; Transcriptome; Visceral leishmaniasis
Mesh:
Substances:
Year: 2017 PMID: 29035735 PMCID: PMC5645162 DOI: 10.1016/j.ijpddr.2017.10.004
Source DB: PubMed Journal: Int J Parasitol Drugs Drug Resist ISSN: 2211-3207 Impact factor: 4.077
Fig. 1Drug susceptibility of PMM-R and the corresponding WT parasites: Sensitivity profile of three PMM resistant and their respective wild type isolates towards PMM at A. promastigote and B. amastigote stage. IC50 and IC90 values are the mean of three independent experiments performed in triplicate.
Fig. 2A. Comparative gene expression of PMM-S and PMM-R parasite on chromosomal map. Chromosome map for expression data was generated using Custom R program. Red and green lines indicate up regulated and down-regulated genes in PMM-R parasite, respectively, while gray lines show the genes that are equally expressed in both samples and white regions represent those not hybridized to the probe. Chromosomes showing high up regulation in PMM resistance included Chromosome 12 and Chromosom 36 whereas high down regulation is evident on Chromosome 23. B. Distribution of genes differentially modulated during PMM resistance in Overall distribution of genes shows total number of unique genes up-regulated or down-regulated is 2.9%. GO categories of genes differentially expressed in PMM-R parasite suggest that genes belonging to metabolic process, electron transport chain/oxidation-reduction, cell surface proteins, stress proteins, cell movement and transporter activity were affected. Unclassified proteins include hypothetical proteins (proteins with unknown function and not tested experimentally) and proteins with no GO categories (unclassified) that have been experimentally characterized. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 3Susceptibility of PMM-R isolates in presence of inhibitors to ABC transporter.In vitro susceptibility towards PMM in presence of verapamil (Vera) and amlodipine (Amlo) in three different PMM-Rand WT isolates at A. Promastigote stage and B. Amastigote stage. Each individual value represents mean fold change in IC50 ± SD of the results from three separate assays in duplicates. * represents p = 0.05, ** represents p = 0.01, *** represents p = 0.001.
Fig. 4Predicted adaptations in Genes altered in PMM-R parasites are represented here. Genes marked with up and down arrow represent respectively the up-regulated genes and the down-regulated genes in PMM-R parasites. 1,2,3,4 and 5 are probable adaptations in PMM-R parasites.1. Down-regulation of oxidative phosphorylation leads to reduced influx of PMM drug, 2. Enzyme for glycolysis and glycosomal succinate fermentation were up-regulated indicating increased substrate level phosphorylation, 3. Down-regulated DNA polymerase θ suggesting reduced DNA synthesis. Hypo. protein responsible for DNA damage repair were up-regulated 4.Tryptophenyl-t-RNA synthatase and several ribosomal proteins were down-regulated suggesting reduced protein synthesis, Down-regulation of metallo-and carboxipeptidases indicated reduced protein degradation, 5. Up-regulation of ABC transporters and reversion of resistant phenotype in presence of modulators, verapamil or amlodipine suggested probable role of ABC transporters in selection of PMM resistance. Abbreviations used are as follows: 2-PG, 2-phosphoglycerate; 3-PG, 3-phosphoglycerate; AA t-RNA Synthetase, Aminoacyl t-RNA Synthetase; Ac CoA, Acetyl Coenzyme A; ALAT, Alanine aminotransferase; CMDH, Cytosolic malate dehydrogenase; DNA pol. θ, DNA Polymerase θ; Fructose-6-P, Fructose-6-phospahet; Glucose-6-P, Glucose-6-phosphate; GSH, Glutathione; Hypo. Protein, Hypothetical protein; IDH, Isocitrate dehydrogenase; NUO, NADH ubiquinone oxidoreductase; PEP, Phosphoenol pyruvate; PEPCK, Phosphoenol pyruvate carboxykinase; SDH, Succinate dehydrogenase; TrS, Trypanothione synthetase.